-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Neutral on Bristol-Myers Squibb, Raises Price Target to $70

Benzinga·08/03/2026 18:40:03
Listen to the news
Citigroup analyst Geoff Meacham maintains Bristol-Myers Squibb (NYSE:BMY) with a Neutral and raises the price target from $66 to $70.